Document Detail


Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
MedLine Citation:
PMID:  19425084     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Levodopa (L-dopa) administered with a dopadecarboxylase inhibitor (DDI) increases homocysteine plasma levels. This may support the onset of atherosclerosis-related disorders and neuropsychiatric complications in patients with Parkinson's disease (PD). This homocysteine elevation is considered as long-term effect of chronic L-dopa/DDI treatment. Little is known about the acute effects of L-dopa/DDI intake on homocysteine generation. The objective of this trial was to investigate the relations between L-dopa and homocysteine after acute L-dopa/DDI administration in PD patients with different L-dopa metabolism. Thirty PD patients were divided into groups with superior (I) and less (II) L-dopa absorption after standardized intake of 125 mg L-dopa/benserazide with determination of L-dopa, 3-O-methyl-dopa (3-OMD) and homocysteine in plasma at baseline, 30, 60, and 90 minutes. There was a homocysteine increase in Group I (F = 5; P = 0.005) and a moderate decrease in Group II (F = 4.27; P = 0.01). A rise of 3-OMD (F = 10.51; P < 0.0001) appeared in Group I, but not in Group II (F = 0.91; P = 0.44), accordingly L-dopa accumulation was better in Group I than in Group II. Thus, in conclusion, L-dopa metabolism is an important component for homocysteine elevation after one time L-dopa/DDI administration in PD patients.
Authors:
Thomas Müller; Wilfried Kuhn
Related Documents :
21692774 - If serration pattern analysis as a diagnostic criterion in anti-laminin-332 mucous memb...
7893854 - Altered heart rate variability in panic disorder patients.
22574854 - Diagnosis and inflammatory response of patients with candiduria.
22552994 - Neurologic complications in patients with inflammatory bowel disease: increasing releva...
20123314 - The restoration of chronotropic competence in heart failure patients with normal ejecti...
18175664 - Iron supplementation and oxidative stress in patients with uremia.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Movement disorders : official journal of the Movement Disorder Society     Volume:  24     ISSN:  1531-8257     ISO Abbreviation:  Mov. Disord.     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-08-03     Completed Date:  2009-10-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8610688     Medline TA:  Mov Disord     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1339-43     Citation Subset:  IM    
Copyright Information:
2009 Movement Disorder Society.
Affiliation:
Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Germany. th.mueller@alexius.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Analysis of Variance
Antiparkinson Agents / administration & dosage*,  blood
Dihydroxyphenylalanine / analogs & derivatives,  blood
Female
Homocysteine / blood*
Humans
Levodopa / administration & dosage*,  blood
Male
Middle Aged
Parkinson Disease / blood*,  drug therapy*
Severity of Illness Index
Statistics as Topic
Time Factors
Chemical
Reg. No./Substance:
0/3-O-methyl-DOPA; 0/Antiparkinson Agents; 0/Levodopa; 454-28-4/Homocysteine; 63-84-3/Dihydroxyphenylalanine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Axon regeneration in the absence of growth cones: acceleration by cyclic AMP.
Next Document:  Bradykinesia, muscle weakness and reduced muscle power in Parkinson's disease.